Cofactor Genomics

Fewer than 20 percent of cancer patients respond to immunotherapy; if clinicians knew which patients would respond to which therapies, they could make far more precise recom­men­da­tions. Cofactor Genomics found 40 genes that make up each patient’s core immune profile. Using machine learning to analyze multiple RNA biomarkers in solid tumor tissue, the company can tell which patients with conditions such head and neck squamous cell carcinoma, non-small-cell lung cancer, colorectal cancer, or urothelial carcinoma have actionable mutations that will likely respond to modern immunotherapies.